Filana's IND hold response offers a live case study in FDA strategy

Filana Therapeutics is navigating an active FDA Clinical Hold Letter on its simufilam IND while simultaneously presenting the program's scientific rationale to the international epilepsy community, a dual-track posture that regulatory affairs teams managing IND holds will recognise as both necessary and instructive.

Filana presents simufilam TSC program at Eilat XVIII

At the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII), held in Madrid, Spain, Filana Therapeutics delivered a scientific presentation outlining the biological rationale for evaluating simufilam in tuberous sclerosis complex (TSC)-related epilepsy. The conference is a recognised international forum for antiepileptic drug development, and the presentation centred on the mTOR pathway dysregulation that underlies TSC seizure activity.

TSC is a rare genetic disorder caused by mutations in the TSC1 or TSC2 genes, affecting the mechanistic target of rapamycin (mTOR) pathway and driving tumour growth across multiple organs. Epilepsy is the predominant clinical burden: 80–90% of TSC patients experience seizures, approximately 45,000 people in the U.S. are affected by TSC-related epilepsy, and more than 60% remain refractory to existing antiepileptic therapies. Simufilam targets filamin A protein modulation, a mechanism supported by preclinical seizure-reduction data published in Science Translational Medicine (Zhang et al., 2020).

The December 2025 Clinical Hold Letter from FDA requested additional preclinical data and protocol design modifications before the IND can proceed. Filana is currently completing those submissions and expects to file its formal FDA response in the coming months, at which point a program update will follow.

The compliance read for regulatory teams managing active IND holds

For regulatory affairs leads, Filana's situation maps directly onto the structured response obligations under 21 CFR Part 312.42, which governs clinical hold procedures and sponsor response requirements. The company's disclosed approach, submitting additional preclinical data alongside protocol redesign, reflects the two most common FDA hold-resolution pathways: addressing safety data gaps and modifying study design to reduce subject risk.

The decision to present publicly at Eilat XVIII while the hold remains active is a calculated stakeholder-management move. It preserves scientific credibility with the epilepsy clinical community and signals program continuity without making regulatory commitments the company cannot yet support. Regulatory leads managing similar holds should note that public scientific engagement and FDA response preparation are not mutually exclusive activities, provided forward-looking statements are appropriately qualified.

The preclinical data submission requirement also has CMC and nonclinical study implications. Teams should assess whether existing GLP study packages are sufficient to address the hold's information requests, or whether new studies, and the associated timelines, are required before a complete response can be filed.

When Filana's FDA response lands, and what follows

Filana has indicated a response submission to FDA is expected within the coming months, with a program update to follow. Under 21 CFR Part 312.42(e), FDA has 30 days to review a sponsor's complete response to a clinical hold and notify the sponsor whether the hold has been lifted. That 30-day review clock does not start until FDA determines the response is complete, making the quality and completeness of Filana's preclinical data package and protocol modifications the critical near-term variable.

Regulatory affairs teams tracking this program should monitor Filana's next public disclosure for confirmation that the response has been submitted, which will set the outer boundary of the FDA review window and indicate whether the IND is on track for reinstatement ahead of any planned clinical site activation.

The 30-day FDA review period following Filana's complete response submission is the measurable checkpoint that will determine whether simufilam advances into clinical evaluation in TSC-related epilepsy.